Replimune Group (NASDAQ:REPL) Insider Sells $148,467.59 in Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Konstantinos Xynos sold 11,447 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,467.59. Following the completion of the sale, the insider owned 224,215 shares of the company’s stock, valued at approximately $2,908,068.55. The trade was a 4.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Down 1.4%

REPL stock opened at $14.97 on Friday. Replimune Group, Inc. has a twelve month low of $1.50 and a twelve month high of $15.70. The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.63. The stock has a market cap of $1.26 billion, a P/E ratio of -4.43 and a beta of 0.88. The business’s 50-day moving average price is $10.66 and its 200-day moving average price is $7.79.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). On average, equities research analysts forecast that Replimune Group, Inc. will post -2.7 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on REPL. JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $17.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 23rd. Weiss Ratings cut shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Finally, Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price for the company in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Replimune Group currently has an average rating of “Moderate Buy” and a consensus target price of $11.86.

Institutional Investors Weigh In On Replimune Group

Several large investors have recently made changes to their positions in the company. EcoR1 Capital LLC purchased a new stake in shares of Replimune Group in the first quarter worth about $7,650,000. Seven Fleet Capital Management LP purchased a new position in Replimune Group during the 1st quarter valued at approximately $921,000. Jefferies Financial Group Inc. purchased a new position in Replimune Group during the 4th quarter valued at approximately $6,942,000. Candriam S.C.A. bought a new stake in Replimune Group in the 1st quarter worth approximately $3,014,000. Finally, Persistent Asset Partners Ltd bought a new stake in Replimune Group in the 4th quarter worth approximately $598,000. 92.53% of the stock is owned by institutional investors.

Key Stories Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: FDA approval creates a commercial opportunity: Replimune announced that TUDRIQEV™ (RP1) in combination with nivolumab received FDA accelerated approval for advanced melanoma. The company expects to launch the treatment within 60 days, potentially allowing it to begin generating commercial revenue and validating its oncolytic-immunotherapy platform. Replimune fiscal first-quarter 2027 results and corporate update
• Positive Sentiment: Financing supports the launch: A recently completed $150 million financing extends Replimune’s cash runway and is intended to fund the commercial rollout and confirmatory trial required under the accelerated-approval pathway. The added liquidity reduces near-term funding concerns, though the offering may dilute existing shareholders. Replimune corporate update
• Positive Sentiment: Commercial leadership added: Michelle DiNapoli was appointed chief commercial officer, strengthening the company’s preparations for its first product launch.
• Neutral Sentiment: Insider sales were attributed to taxes: The CEO, CFO, CAO and another insider sold shares totaling approximately $906,000. SEC filings indicate the transactions covered tax withholding tied to vested equity awards, and the executives retained significant holdings, limiting the negative signal.
• Negative Sentiment: Quarterly loss slightly exceeded expectations: Replimune reported a fiscal first-quarter loss of $0.72 per share versus the consensus estimate of a $0.69 loss. As a commercial-stage biotechnology company, it remains unprofitable and is expected to post a substantial full-year loss.
• Negative Sentiment: Securities litigation remains an overhang: Multiple law firms are promoting a class action covering investors who bought REPL shares from October 20, 2025, through April 10, 2026. The lawsuit alleges misleading statements about RP1 and FDA study-design issues; the allegations have not been proven. The lead-plaintiff deadline is October 5, 2026. Replimune securities lawsuit deadline alert

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.